.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,011,068

« Back to Dashboard
Patent 6,011,068 protects SENSIPAR and is included in one NDA. There has been one Paragraph IV challenge on Sensipar. There are three tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has one hundred and eleven patent family members in twenty-seven countries.

Summary for Patent: 6,011,068

Title: Calcium receptor-active molecules
Abstract:The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca.sup.2+ and the effect is on a cell having a calcium receptor; (2) inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorganic ion receptor proteins, preferably calcium receptor protein; and (5) uses of such molecules, proteins, nucleic acids and antibodies.
Inventor(s): Nemeth; Edward F. (Salt Lake City, UT), Van Wagenen; Bradford C. (Salt Lake City, UT), Balandrin; Manuel F. (Sandy, UT), DelMar; Eric G. (Salt Lake City, UT), Moe; Scott T. (Salt Lake City, UT)
Assignee: NPS Pharmaceuticals, Inc. (Salt Lake City, UT) The Brigham and Women's Hospital (Boston, MA)
Application Number:08/353,784
Patent Claim Types:
see list of patent claims
Compound; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-001Mar 8, 2004RXNo6,011,068► subscribeYY
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-002Mar 8, 2004RXNo6,011,068► subscribeYY
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-003Mar 8, 2004RXYes6,011,068► subscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,011,068

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,313,146 Calcium receptor-active molecules► subscribe
5,962,314 Calcium receptor-active molecules► subscribe
5,763,569 Calcium receptor-active molecules► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,011,068

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria264292► subscribe
Austria287390► subscribe
Austria312347► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc